中东和非洲消化不良药物市场，按类型（器质性消化不良、非溃疡性消化不良、药物引起的消化不良等）、治疗类型（药物和手术）、药物类型（品牌和通用）、处方（非处方药和处方药）、给药途径（口服和注射）、性别（男性和女性）、最终用户（医院、诊所、家庭护理机构、专科诊所、门诊手术中心、学术和政府研究机构等）、分销渠道（直接招标和零售销售）划分 - 行业趋势和预测到 2030 年。
中东和非洲
中东和非洲痢疾毒品市场预计在预测期间会增长,原因是痢疾的流行率不断上升,不健康的生活方式日益被采用。 市场也受到了代谢失调症发病率上升的影响. 然而,中东和非洲痢疾药物市场预计会受到下列因素的阻碍:用于痢疾的药物可能产生的副作用,以及越来越倾向于自然和草药疗法。 日益老龄化的人口和药物批准量的增加预计将成为市场增长的机会。 然而,严格的条例和民众对痢疾缺乏认识,预计将给市场增长带来挑战。
数据桥市场研究分析认为,预计在2023至2030年的预测期间,中东和非洲底苯丙胺药物市场将以3.0%的CAGR增长.
|
报表计量 |
细节 |
|
预测期 |
2023年至2030年统计 |
|
基准年 |
2022 |
|
历史年代 |
2021 (2015-2020年可定制). |
|
数量单位 |
单位单位收入和定价 |
|
覆盖部分 |
类型(组织性Dyspepsia、非Ulcer Dyspepsia、由药物诱导的Dyspepsia等)、治疗类型(医疗和外科)、药物类型(常规和普通)、处方(无处方药和处方药)、管理途径(口服和注射药)、性别(男用和女用)、最终用户(医院、诊所、家庭护理设施、特别诊所、门诊中心、学术和政府研究所等)、分销渠道(发货和零售销售) |
|
涵盖国家 |
南非、埃及、巴林、阿拉伯联合酋长国、科威特、阿曼、沙特阿拉伯、卡塔尔、中东其他地区和非洲 |
|
覆盖的市场玩家 |
Bayer AG、Cadila制药公司、Sanofi、Lupin、Abbott、Perrigo Company plc、AstraZeneca、Procter & Gamble和Reckitt Benckiser等 |
市场定义
消化道(Dyspepsia),通称消化道,是食后腹部所经历的疼痛和不适. 它通常是一种基本病症的征兆,如GERD(气管还原性疾病)、胆固醇和溃疡疾病等。 糖尿病的治疗取决于病因和严重程度。 治疗某种基本病症或改变一个人的药物会减少发作. Dyspepsia主要分为2个类别:"有机"和"功能性干燥"(FD). 造成痢疾的有机原因有:化脓溃疡、胃溃疡再生疾病、胃癌或食道癌、胰腺或双胞胎失调、对食物或药物的不容忍以及其他传染病或系统性疾病。 功能性失眠症(Dis-PEP-see-uh)是一个术语来指无明显原因的心烦的胃的反复症状. 功能性硬化症也叫非溃疡硬化症.
中东和非洲
本节讨论了解市场驱动力、优势、机会、制约因素和挑战。 下文详细讨论所有这些问题:
驾驶员
- 日益流行的痢疾
消化道(Dyspepsia),通称消化道,是影响中东和非洲数百万人的胃肠道障碍. 此症能使上腹出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出入出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出 食用过快,食用辣或脂肪食品等多种因素,或作为药物的副作用,都可以引起多肽.
痢疾日益普遍,是导致痢疾药物市场增长的关键因素之一. 痢疾发病率上升可归因于生活方式、饮食习惯和人口老龄化等若干因素。 随着人老化,他们更容易被消化问题所感染,包括呼吸道衰竭. 随着老年人数的不断增长,对痢疾药物的需求也有所增加.
此外,不同的消化道疾病,如易发性肠道综合征,胃病,胃溃疡病和化脓性溃疡病等,也因上述疾病的发病率不断上升而引起痢疾. 因此,造成痢疾的痢疾和其他消化障碍的日益流行,可望成为市场增长的动力。 使用痢疾药物来缓解痢疾的症状并治疗痢疾,有潜力改善患者的结果并减轻痢疾的负担. 因此,痢疾的日益普遍正在推动全世界对痢疾药物的需求,从而增加痢疾在人口中的发病率和流行率。
- 采取不健康的生活方式
近年来,不健康的生活方式的采用率上升了,这助长了痢疾的流行. 健康不良的生活方式选择,如加工食品中高膳食,缺乏锻炼,酒精消费过量等,都可能造成痢疾.
因此,随着人们寻求缓解其症状,对痢疾药物的需求也相应增加. 德丙类药物市场通过各种药物,包括质子泵抑制剂,H2受体对抗剂和安打剂,来响应这种需要.
采取不健康的生活方式的上升可归因于若干因素,包括饮食习惯的改变、压力程度的提高和定居的生活方式。 现代生活的特点是工作时间长,压力大,容易获得快餐和其他不健康的选择。 这些因素可导致呼吸道失常和其他相关疾病,如胃溃疡再生病(GERD).
总之,痢疾是一种常见的病症,可能由各种因素所引起,包括不健康的生活方式选择. 采用不健康生活方式的兴起促使了白喉的流行,对有效白喉药物的需求也相应增加,预计将成为市场增长的动力.
机会
- 人口老龄化
根据估计,到2050年,65岁及以上的人口预计将达到15亿,这表明世界人口正在迅速老化并不断老化。 随着年龄的增长,人们患慢性病的风险更高。 这包括消化障碍等可因衰老而发作的呼吸道障碍.
人口不断增长和老化,为扩大痢疾毒品市场提供了重要机会。 由于越来越多的人对其消化系统有问题,因此越来越需要有效的治疗,可以降低症状的严重性并提高其整体生活质量.
此外,对痢疾的治疗可能需要专门针对老龄人口的需要。 老年人有可能患有多起慢性病并同时服用多起药物,两者都可能增加药物负相互作用和副作用的可能性. 因此,人们需要抗痢药物,这些药物对老年人既无风险又有效。 老年人还丧失了身体和免疫力,导致包括痢疾在内的多起与胃有关的疾病日益流行。
因此,老年人口的增加会引起痢疾及其症状,人们更喜欢预防性保健,这有望成为痢疾药物市场增长的机会。
重排/挑战
- 民众对痢疾缺乏认识
缺乏技能已经影响到国家,越来越多的人被迫等待6个多月的口腔治疗。 由于技术进步、基本基础设施和若干其他因素,新兴或发展中国家缺乏Dyspepsia Drug领域的熟练专业人员。
缺乏熟练的专业人员,部分原因是需要严格的教育和培训才能成为牙科专业人员以及竞争性的就业市场。 此外,技术熟练的牙医需要更多受过正规培训、有执照的牙医助理,帮助维持和增加口腔保健,以便操作和执行先进的技术系统,如痢疾药物系统。
新兴国家缺乏无法有效操作新技术的熟练专业人员。 这可能给市场带来出现新技术的挑战,因为这些国家正在拖延技术驱动的市场进步的开始。
最近的事态发展
- 2023年4月,萨诺菲宣布已经完成了对Provention Bio股份有限公司的收购. 这一收购帮助了公司扩展了通医业务.
- 2022年7月,ANI制药股份有限公司宣布从一家私人拥有的生化制药公司Oakrum Pharma(LLC)购买了4个缩写的新药应用(ANDAs).
中东和非洲
中东和非洲痢疾药物市场分为类型、治疗类型、药物类型、处方、管理路线、性别、最终用户和分销渠道。 不同部门之间的增长有助于你分析特殊的增长领域和接近市场的战略,并确定你的核心应用领域以及目标市场的差异。
类型
- 非紫外线
- 有机针叶虫
- 诱导的药物
- 其他人员
根据类型,中东与非洲德丙类药物市场被分入有机德丙类药物,非溃疡德丙类药物,由药物诱发德丙类药物等.
治疗类型
- 药品
- 外科手术
根据治疗类型,中东和非洲痢疾药物市场被分为药物和外科。
药物类型
- 品牌
- 常规
根据中东和非洲毒品类型,毒品市场被分割成通用的并被打上烙印。
处方
- 无处方药
- 处方药
根据处方,中东和非洲痢疾药物市场被分割成没有处方药和处方药。
行政路线
- 口头
- 可注射
根据管理路线,中东和非洲痢疾药物市场分为口服和注射。
性别
- 男性
- 妇女
根据性别,中东和非洲痢疾毒品市场分为男性和女性。
结束用户
- 医院
- 诊所
- 家庭护理设置
- 专科诊所
- 救护车中心
- 学术和政府研究所
- 其他人员
根据最终用户情况,中东和非洲痢疾药物市场分为医院、诊所、家庭护理场所、专科诊所、流动外科中心、学术和政府研究机构等。
分发频道
- 直接招标
- 零售
根据分销渠道,中东和非洲二联药物市场分为直接招标和零售。
中东和非洲
对中东和非洲痢疾药物市场进行了分析,并根据类型、治疗类型、药物类型、处方、管理路线、性别、最终用户和分销渠道提供了市场规模的见解和趋势。
本市场报告涵盖的国家有:南非、埃及、巴林、阿拉伯联合酋长国、科威特、阿曼、沙特阿拉伯、卡塔尔、中东其他地区和非洲。
预计南非将主导中东和非洲痢疾毒品市场,因为痢疾毒品与发展领域的研究日益增加。
报告的国家部分还提供了影响市场的因素和影响市场当前和未来趋势的市场监管变化。 下游和上游价值链分析,技术趋势,波特五力分析等数据点,以及案例研究,是用来预测个别国家市场情景的一些指针. 此外,在对国家数据进行预测分析的同时,还考虑了中东和非洲品牌的存在和可得性,以及它们因来自当地和国内品牌的大规模或稀缺竞争而面临的挑战,以及国内关税和贸易路线的影响。
竞争性景观与中东和非洲
中东和非洲大便药市场竞争环境提供了竞争对手的详细情况。 详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、中东和非洲的存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度以及应用优势。 上述数据点仅涉及公司对市场的关注。
在市场上经营的一些主要市场参与者有:拜耳AG,卡迪拉制药公司.,萨诺菲,吕平.,阿博特.,佩里戈公司plc,AstraZeneca,Procter & Gamble,以及雷克基特·本克西泽等.
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA
7 INDUSTRY INSIGHTS:
8 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, REGULATION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS
9.2 RESTRAINTS
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES
9.3 OPPORTUNITIES
9.3.1 GROWING AGING POPULATION
9.3.2 RISE IN THE DRUG APPROVAL
9.4 CHALLENGES
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION
9.4.2 STRINGENT REGULATIONS
10 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE
10.1 OVERVIEW
10.2 NON-ULCER DYSPEPSIA
10.3 ORGANIC DYSPEPSIA
10.4 DRUG INDUCED DYSPEPSIA
10.5 OTHERS
11 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 DRUGS
11.2.1.1 ANTACIDS
11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S)
11.2.1.1.1.1 OMEPRAZOLE
11.2.1.1.1.2 LANSOPRAZOLE
11.2.1.1.1.3 ESOMEPRAZOLE
11.2.1.1.1.4 OTHERS
11.2.1.1.2 H2 BLOCKERS
11.2.1.1.2.1 CIMETIDINE
11.2.1.1.2.2 FAMOTIDINE
11.2.1.1.2.3 NIZATIDINE
11.2.1.1.2.4 RANITIDINE
11.2.1.1.2.5 OTHERS
11.2.1.2 GASTRIC PROKINETIC GENDERNTS
11.2.1.2.1 MOSAPRIDE CITRATE
11.2.1.2.2 METOCLOPRAMIDE
11.2.1.2.3 CISAPRIDE
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE
11.2.1.2.5 DOMPERIDONE
11.2.1.2.6 OTHERS
11.2.1.3 ANTIBIOTICS
11.2.1.3.1 REFAXIMIN
11.2.1.3.2 AMOXICILLIN
11.2.1.3.3 CLARITHROMYCIN
11.2.1.3.4 METRONIDAZOLE
11.2.1.3.5 LEVOFLOXACIN
11.2.1.3.6 TETRACYCLINE
11.2.1.3.7 OTHERS
11.2.1.4 OTHERS
11.2.2 NON- DRUGS
11.2.2.1 PROBIOTICS
11.2.2.1.1 LACTOBACILLUS
11.2.2.1.2 BIFIDOBACTERIUM
11.2.2.1.3 BACILLUS
11.2.2.1.4 STREPTOCOCCUS
11.2.2.1.5 OTHERS
11.2.2.2 PREBIOTICS
11.3 SURGERY
12 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERIC
12.3 BRANDED
13 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION
13.1 OVERVIEW
13.2 WITHOUT PRESCRIPTION DRUGS
13.3 PRESCRIPTION DRUGS
14 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS
14.2.2 CAPSULES
14.3 INJECTABLE
15 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY GENDER
15.1 OVERVIEW
15.2 FEMALE
15.2.1 30-50 YEARS
15.2.2 MORE THAN 50 YEARS
15.2.3 AGE LESS THAN 30
15.3 MALE
15.3.1 30-50 YEARS
15.3.2 MORE THAN 50 YEARS
15.3.3 AGE LESS THAN 30
16 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 TYPE
16.2.1.1 PUBLIC
16.2.1.2 PRIVATE
16.2.2 TIER
16.2.2.1 TIER 3
16.2.2.2 TIER 2
16.2.2.3 TEIR 1
16.3 CLINICS
16.4 HOMECARE SETTINGS
16.5 SPECIALTY CLINICS
16.6 AMBULATORY CENTERS
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
16.8 OTHERS
17 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 RETAIL SALES
17.2.1 REATIL PHARMACY
17.2.2 HOSPITAL PHARMACY
17.2.3 ONLINE PHARMACY
17.3 DIRECT TENDER
18 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY REGION
18.1 MIDDLE EAST AND AFRICA
18.1.1 SOUTH AFRICA
18.1.2 EGYPT
18.1.3 BAHRAIN
18.1.4 U.A.E
18.1.5 SAUDI ARABIA
18.1.6 KUWAIT
18.1.7 OMAN
18.1.8 QATAR
18.1.9 REST OF MIDDLE EAST AND AFRICA
19 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
20 SWOT ANALYSIS
21 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS
21.1 SANOFI
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENT
21.2 LUPIN
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 MANKIND PHARMA
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 ASTRAZENECA
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 BAYER AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENT
21.6 ABBOTT
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ANI PHARMACEUTICALS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTERISK LABORATORIES (I) PVT. LTD
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENT
21.1 CADILA PHARMACEUTICALS
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 COMPANY SHARE ANALYSIS
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENT
21.11 HANMI PHARM. CO., LTD.
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENT
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 OTSUKA PHARMACEUTICAL CO., LTD.
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 PERRIGO COMPANY PLC
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 PRESTIGE CONSUMER HEALTHCARE, INC.
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENT
21.16 PROCTER & GAMBLE
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
21.17 RECKITT BENCKISER.
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 REDHILL BIOPHARMA LTD
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SALIX PHARMACEUTICALS OR ITS AFFILIATES (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENT
21.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 WOODWARD PHARMA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 ZERIA PHARMACEUTICAL CO., LTD.
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 55 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 57 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 59 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 61 MIDDLE EAST AND AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 64 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 76 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 SOUTH AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 SOUTH AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 SOUTH AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 83 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 84 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 86 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 87 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 89 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 90 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 91 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 92 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 93 SOUTH AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 96 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 97 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 99 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 100 SOUTH AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 101 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 102 SOUTH AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 103 SOUTH AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 104 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 105 SOUTH AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 SOUTH AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 107 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 108 SOUTH AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 109 EGYPT DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 110 EGYPT DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 EGYPT MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 EGYPT DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 EGYPT ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 116 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 117 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 119 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 120 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 122 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 123 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 125 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 126 EGYPT NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 127 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 129 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 130 EGYPT DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 EGYPT DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 132 EGYPT DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 133 EGYPT ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 134 EGYPT DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 135 EGYPT FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 136 EGYPT MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 137 EGYPT DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 138 EGYPT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 EGYPT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 140 EGYPT DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 141 EGYPT RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 142 BAHRAIN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 143 BAHRAIN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 BAHRAIN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 BAHRAIN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 BAHRAIN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 149 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 150 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 152 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 153 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 154 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 155 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 156 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 158 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 159 BAHRAIN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 162 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 163 BAHRAIN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 BAHRAIN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 165 BAHRAIN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 166 BAHRAIN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 167 BAHRAIN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 168 BAHRAIN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 169 BAHRAIN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 170 BAHRAIN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 171 BAHRAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 BAHRAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 173 BAHRAIN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 174 BAHRAIN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 175 U.A.E DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 U.A.E DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 U.A.E MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 U.A.E DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 179 U.A.E ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 182 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 183 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 184 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 185 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 186 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 188 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 189 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 191 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 192 U.A.E NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 195 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 196 U.A.E DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 U.A.E DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 198 U.A.E DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 199 U.A.E ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 200 U.A.E DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 201 U.A.E FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 202 U.A.E MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 203 U.A.E DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 204 U.A.E HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 U.A.E HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 206 U.A.E DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 207 U.A.E RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 208 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 SAUDI ARABIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 211 SAUDI ARABIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 SAUDI ARABIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 215 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 216 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 217 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 218 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 219 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 221 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 222 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 223 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 224 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 225 SAUDI ARABIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 228 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 229 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 230 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 231 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 232 SAUDI ARABIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 233 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 234 SAUDI ARABIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 235 SAUDI ARABIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 236 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 237 SAUDI ARABIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 238 SAUDI ARABIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 239 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 240 SAUDI ARABIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 241 KUWAIT DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 242 KUWAIT DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 243 KUWAIT MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 244 KUWAIT DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 KUWAIT ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 248 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 249 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 251 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 252 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 254 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 255 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 257 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 258 KUWAIT NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 260 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 261 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 262 KUWAIT DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 263 KUWAIT DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 264 KUWAIT DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 265 KUWAIT ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 266 KUWAIT DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 267 KUWAIT FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 268 KUWAIT MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 269 KUWAIT DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 270 KUWAIT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 271 KUWAIT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 272 KUWAIT DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 273 KUWAIT RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 274 OMAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 OMAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 OMAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 OMAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 OMAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 279 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 280 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 281 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 282 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 284 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 285 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 286 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 287 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 288 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 290 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 291 OMAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 293 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 294 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 295 OMAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 OMAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 297 OMAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 298 OMAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 299 OMAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 300 OMAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 301 OMAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 302 OMAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 303 OMAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 304 OMAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 305 OMAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 306 OMAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 307 QATAR DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 308 QATAR DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 309 QATAR MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 310 QATAR DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 311 QATAR ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 313 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 314 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 315 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 316 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 317 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 318 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 319 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 320 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 321 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 322 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 323 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 324 QATAR NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 325 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 326 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 327 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 328 QATAR DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 329 QATAR DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 330 QATAR DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 331 QATAR ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 332 QATAR DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 333 QATAR FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 334 QATAR MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 335 QATAR DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 336 QATAR HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 337 QATAR HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 338 QATAR DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 339 QATAR RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 340 REST OF MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 8 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET
FIGURE 15 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE, 2022
FIGURE 16 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 17 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 18 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022
FIGURE 20 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 21 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)
FIGURE 22 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022
FIGURE 24 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 25 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 26 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022
FIGURE 28 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)
FIGURE 29 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)
FIGURE 30 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 32 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 33 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 34 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY GENDER, 2022
FIGURE 36 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 37 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY END USER, 2022
FIGURE 40 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 41 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 45 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)
FIGURE 48 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)
FIGURE 49 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)
FIGURE 52 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
